Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00168753 · ClinicalTrials.gov registry record · Phase 4

Community Based Trial for AMEVIVE®

A Phase 4 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 4
Development phase
114
Enrollment target

NCT00168753 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 114 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00168753, a Phase 4 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 4
Development phase
114 participants
Enrollment target

Study Summary

To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.

Interventions

  • DRUG Alefacept

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2004-07
Est. Completion 2005-03
Phase Phase 4

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT00168753

The ClinicalTrials.gov registry entry for NCT00168753 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Alefacept is the first listed.

NCT00168753 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00168753 about?

NCT00168753 is a clinical study titled "Community Based Trial for AMEVIVE®". To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.

What is the current status of trial NCT00168753?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2004-07. Estimated completion is 2005-03.

What interventions are being tested in trial NCT00168753?

The interventions under investigation include: Alefacept (DRUG).

Who is sponsoring clinical trial NCT00168753?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.